The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Yi-Bin ChenDuring the 2023 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the GvHD Hub was pleased to speak to Yi-Bin Chen, Massachusetts General Hospital, Boston, US. We asked, Is vedolizumab effective for preventing lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD)?
Is vedolizumab effective for preventing lower GI acute GvHD?
Chen begins by summarizing the justifications, methods, and data from the phase III randomized, double blind, placebo-controlled GRAPHITE trial of vedolizumab. GRAPHITE was a prospective large cohort trial with a primary endpoint of lower GI aGvHD-free survival by Day 180. Chen explains the trials clinical significance, highlighting overall survival, relapse free survival, and safety.
Chen concludes by discussing the impact of current clinical trials on future treatment and prevention strategies for GvHD, as well as the impact of new interventions on patient populations.